CEO Peter Luo no longer attributed beneficial ownership of 11.20% stake held by family trust
ADAG has more than doubled off its 52-week low of $1.3.
Summary
CEO Peter Luo and Xiaohong She are no longer attributed beneficial ownership of an 11.20% stake in Adagene Inc. held by a family trust, following a trustee change.
Key Events · Ownership and Investor Activity · ADAG
-
CEO's Attributed Ownership Reduced
CEO Peter Luo and Xiaohong She are no longer deemed to beneficially own the 11.20% stake (9,390,439 shares) held by the HAN 2020 Irrevocable Trust.
-
Trustee Change for Family Trust
The change in beneficial ownership attribution stems from a December 19, 2024, trustee change for the HAN 2020 Irrevocable Trust, where North Point Trust Company became the independent trustee.
-
Significant Stake Value
The 11.20% stake, no longer attributed to the CEO, is valued at approximately $32.6 million based on the current stock price, representing a substantial portion of the company's market capitalization.
Analysis · ADAG · Life Sciences
This Schedule 13D/A reports a significant change in the beneficial ownership attribution for CEO Peter Luo and Xiaohong She. Due to a trustee change for the HAN 2020 Irrevocable Trust on December 19, 2024, the 11.20% stake held by the trust is no longer attributed to them. While the shares remain within a family trust, this represents a material reduction in the reported direct control and influence of the CEO over a substantial portion of the company's shares.
At the time of this filing, ADAG was trading at $3.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157.3M. The 52-week trading range was $1.30 to $4.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.